A 2 Part Open-Label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2015
At a glance
- Drugs GW 842166X (Primary)
- Indications Inflammatory pain; Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 15 Feb 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 10 Oct 2007 New trial record.